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1. Introduction 
A large number of reports about the health benefits of probiotics could be found in the 
PubMed database. Very little information is available about probiotics possessing physio-
logically relevant antioxidative properties. Quite scarce is information on the influence of 
probiotics on human body oxidative stress status and a limited number of clinical trials have 
been conducted on the effect of antioxidative lactic acid bacteria on human oxidative stress-
driven cardiovascular disease-related aspects. In this chapter possibilities of antioxidative 
probiotics to influence on oxidative stress status in human body are discussed.  
2. Short survey of probiotics 
The potential life-lengthening properties of lactic acid bacteria (LAB) were proposed by 
Metchnikoff already at the beginning of the 20th century. The term “probiotic” is an 
etymological hybrid derived from Greek and Latin meaning “for life” (Hamilton-Miller et 
al., 2003). Today probiotics are defined as live microorganisms which, when consumed in 
appropriate amounts, confer a health benefit on the host (FAO/WHO, 2002). Genera most 
commonly used as probiotics are Lactobacillus and Bifidobacterium, but other LAB such as 
lactococci, streptococci, enterococci as well as propionibacteria, bacilli (e.g. Bacillus subtilis) 
and yeasts (e.g. Saccharomyces boulardii) are applied. However, probiotics are usually LAB. 
Introducing a new probiotic into the market involves a step-wise process in order to obtain a 
functional and safe product (Saarela et al., 2000; Vankerckhoven et al., 2008). Exact 
requirements are set for probiotic bacteria. Centuries-long use of LAB in the food industry 
has proven their safety. Nevertheless, it is compulsory to test the safety of each new 
potential probiotic. The recommendations include an absence of hemolytic activity and the 
transferable antibiotic resistance of the selected strain, while safety should be proven in 
various animal models (FAO/WHO, 2002; Vesterlund et al., 2007; Kõll et al., 2010). There is 
a necessity for pilot clinical trials on healthy volunteers to exclude the adverse effects of 
probiotic administration on gut health, biochemical and cellular indices of blood reflecting 
the proper functions of human organs (Reid, 2005; Rijkers et al., 2010). Probiotics must be 
able to resist stomach acid, bile and the effects of digestive enzymes. Thus, potential 
probiotic candidates will be selected mostly from human normal microflora. The ability to 
survive in the GI tract, adhere to intestinal epithelium and maintain its metabolic activity is 
directly related to the manifestation of probiotic properties in the human body. Probiotic 
properties are strictly strain-specific. Even the related microbial species may have very 
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different clinical effects. Thus, one cannot arbitrarily attribute the properties of one probiotic 
strain to another, even within the same species (Vaughan et al., 2005). 
Probiotic effects have a dosage threshold. The minimum effective dose, which affects the 
intestinal environment and provides beneficial effects on human health, is considered to be 
106-109 live microbial cells per day. The minimum dose depends on the particular strain and 
the type of foodstuffs (Reid, 2005, Williams, 2010, Champagne et al., 2011). Probiotics have 
been demonstrated to be effective in a variety of conditions including the relaxation of 
intestinal discomfort (bloating and pain), the alleviation of chronic intestinal inflammatory 
diseases, the prevention and treatment of pathogen-induced diarrhea, lowering lactose 
intolerance and food allergies, the lowering of cholesterol levels, the prevention of 
urogenital infections and the reduction of atopic diseases (Andersson et al. 2001; Chapman 
et al., 2011). The important area of human physiology that is relevant to functional food 
science according to the ILSI and FUFOSE (the European Commission Concerted Action on 
Functional Food Science in Europe) is, among others, the modulation of the defence against 
high-grade oxidative stress. The latter is one of the principal players in the pathogenesis of 
CVD and other diseases. Thousands of reports reflecting the abovementioned different 
health benefits of probiotics could be found in the databases. However, scarce information is 
available regarding probiotics possessing physiologically relevant antioxidative properties 
and a limited number of clinical trials on the effect of antioxidative LAB on human CVD-
related aspects have been conducted. 
3. Short survey of oxidative stress 
A net of pro-oxidants and the potency of an antioxidant defence system normally balanced 
in the body. Principal pro-oxidants are reactive species (including free radicals) divided into 
reactive oxygen species (ROS) and reactive nitrogen species (RNS) and they mediate the 
main effects of other pro-oxidative factors (Sies, 1991; Halliwell & Gutterridge, 1999). In the 
organisms the crucial ROS are superoxide radical, hydroxyl radical, lipid peroxyl radical 
and non-radical hydrogen peroxide (the latter is produced from superoxide by superoxide 
dismutase) and the principal RNS are nitric oxide and non-radical peroxynitrite. The patho-
logical efficiency of the hydroxyl radical is the most potent and it is rapidly generated via 
the Fenton cycle where free iron (a very potent pro-oxidant) reacts with hydrogen peroxide 
(Halliwell & Gutterridge, 1999). Most of the mentioned reactive species (RS) come from 
endogenous sources as by-products of normal essential metabolic processes, while exoge-
nous sources involve exposure to cigarette smoke, environmental pollutants, radiation, 
drugs, bacterial infections, excess of food iron, dysbalanced intestinal microflora, etc. Several 
diseases are associated with the toxic effect of the transition metals (iron, copper, cadmium). 
Thus, abnormal formation of the RS can occur in vivo and that leads to the damage of lipids, 
proteins, nucleic acids and carbohydrates of cells and tissues. An excessive production of RS 
causes an imbalance in the pro-oxidants/antioxidants system. Any imbalance in favour of 
the pro-oxidants potentially leading to damage was termed ‘oxidative stress’ (Sies, 1991). 
Recently an additional adapted conception of oxidative stress (OxS) was advanced as “a 
disruption of redox signalling and control“(Jones, 2006), emphasizing an impact of the redox 
ratio as good tools for the quantification of OxS. It is remarkable that the glutathione redox 
ratio has a crucial impact concerning this conception. A large body of evidence confirms that 
high-grade OxS is one of the crucial players in the pathogenesis of disorders/diseases (cf 
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below). To maintain the physiological grade of OxS needed for a number’s biofunctions like 
intracellular messaging, growth, cellular differention, phagocytosis, immune response, etc 
the human body has an integrated antioxidative defence system (IADS, Table. 1). Several 
antioxidative components for this human IADS are derived from foodstuffs and provided 
by GI microbiota. Interestingly, it became more and more apparent that the IADS of the host 
and GI microbiota are tightly linked and some specific strains with physiologically effective 
antioxidative activity may have a great impact on the management of the OxS level in the 
gut lumen, inside mucosa cells and even in the host blood, to support the functionality of 
the IADS of the human body. Thus, experiments to find out strains with physiologically 
relevant antioxidative properties/effects as well as trials (including special clinical trials) 
using capsules of such strains or foodstuffs enriched with antioxidative strains are needed. 
Unfortunately, scientific data on probiotic LAB with physiologically relevant antioxidative 
properties is very limited and the data of experiments/trials about both intestinal 
antioxidative protection/influence and systemic antioxidative protection/influence (effects 
of OxS-related indices) are scarce. 
 
Oxidative stressors (pro-oxidants) Integrated antioxidative defence system 
Ischemia/reperfusion 
Smoking, Inflammation, xenobiotics 
PUFA megadoses 
Iron or copper excess 
Radiation, Exhaustive exercises 
Prolonged severe emotional stress 
Vitamin E, C, Q, A 
Enzymes as antioxidants 
(SOD, GPx, CAT, HO1) 
Other antioxidants 
(GSH, plasma albumin, uric acid, 
Bilirubin, carotenoids, etc) 
Table 1. A net effect of oxidative stressors and the potency of the integrated antioxidant 
defence system (IADS) of the body are normally balanced. An imbalance leads to potentially 
harmful oxidative stress. PUFA, polyunsaturated fatty acids; SOD, superoxide dismutase; 
GPx, glutathione peroxidase; CAT, catalase; HO1, haem oxygenase1; GSH, reduced 
glutathione. 
However, as a certain progress has been made during recent years and we will give a 
summarized overview about probiotics and OxS.  
4. Short survey of oxidative stress-related pathological states (CVD, 
metabolic syndrome, allergy, atopic dermatitis, radiation induced problems 
in the intestinal tract) 
A large body of evidence exists that high-grade OxS has one of the crucial roles in the patho-
genesis of disorders/diseases of the vascular system (atherosclerosis, myocardial infarction, 
stroke, peripheral artery disease), the nervous system (Alzheimer’s disease, Parkinson’s di-
sease), the liver (cirrhosis, ethanol damage), the skin (dermatoses), the pancreas (diabetes 
mellitus), metabolic syndrome, obesity, premature ageing, the eyes (age-related macular 
degeneration, retinopathy), development of some tumors and the GI (inflammatory bowel 
disease, coeliac disease, etc), etc (Halliwell & Gutterridge, 1999; Stocker & Keaney, 2004; 
Kals et al., 2006; Stojiljkovic et al., 2007; Krzystek-Korpacka et al., 2008; Tsukahara, 2007; 
Suzuki et al., 2007; Vincent et al., 2007; Castellani et al., 2008). It has recently reviewed that 
harmful GI consequences of radiation therapy have OxS-related background (Spyropoulos 
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et al., 2011). Firstly, radiolysis of water molecules causes rapid production of ROS, secondly, 
an increase in oxygen radical production in the vascular wall has shown already 2h after 
irradiation with a more intense OxS observed at 6h, this second burst being produced 
mainly by infiltrating inflammatory cells (Molla & Panes, 2007). 
Prolonged excessive ROS/RNS production can trigger chemical chain reactions with all 
major biomolecules such as DNA, proteins, and membrane lipids. DNA is affected with a 
variety of lesions like oxidized bases, stand brakes, as well as DNA–DNA and DNA–protein 
cross-links (Barker et al., 2005). Oxidatively damaged proteins are characterized by 
formation of carbonyl groups (Stadtman, 1992). Hydroxyl radicals depolymerize hyaluronic 
acid, degrade collagen, inactivate enzymes and transport proteins via sulfhydryl oxidation. 
RNS may induce nitration of protein tyrosine residues. Lipid peroxidation is the oxidative 
degradation of membrane lipids and oxidation that can cause severe impairment of 
membrane function through changes in membrane permeability and fluidity, its protein 
oxidation, ultimately leading to cell lysis (Halliwell & Gutterridge, 1999). Lipid peroxidation 
also damages blood lipoproteins. Therefore, prolonged high-grade OxS causes damages in 
biomolecules, cells, tissue and organ functionality. Reactive species-damage can be 
evaluated via markers for oxidized proteins (i.e. nitrated tyrosine, protein carbonyls); 
oxidized nucleic acid bases (8-oxo-2-deoxyguanosine), oxidized carbohydrates (glycated 
products) and oxidized lipids (F2-isoprostanes, oxidized low-density lipoproteins (oxLDL), 
etc). Additional approach for investigations of OxS is an assay of the capacity of IADS (i.e. 
assay of total antioxidative status or response (TAS, TAR), etc). All these markers are 
informative but they are not still ultimately accepted as new risk markers yet. However, 
recently pathogenetic relevance of isoprostanes and oxLDL has been accepted (Statements of 
European Food Safety Authority). A large number of articles shows that oxLDL level is 
associated with development of cardiovascular diseases (CVD). Thus, to describe both 
process and status of atherosclerosis common risk markers like low-density lipoprotein or 
LDL-cholesterol, HDL-cholesterol, fasting triglycerides (TG), plasma homocysteine as well 
as by new additional OxS- and inflammation-related indices (oxLDL, 8-isoprostanes, highly 
sensitive C-reactive protein) should be used. All these markers are also diet-related markers 
(Mensink et al., 2003). It is reviewed that OxS indices (oxLDL, urine 8-isoprostanes, etc) 
together with the increased inflammatory markers (white blood cells (WBCs), highly 
sensitive C-reactive protein have been shown to be characteristic of patients with athe-
rosclerotic lesions of the vascular system (Stocker, Keaney, 2004). Consequently, probiotics 
with physiologically relevant multivalent antioxidative properties/effects expressed via a 
positive influence both on a GI and systemic OxS level may have impact concerning the 
pathogenesis of different disorders/diseases, particularly CVD.  
5. Properties of probiotics necessary to have an influence on oxidative stress 
status 
5.1 Role of probiotics in intestinal antioxidative protection (possible action 
mechanisms) 
The most documented effects of LAB in humans are the stimulation of the immune system, 
the prevention and the reduction of the intensity and duration of diarrhea, and reduction of 
lactose intolerance (Wolvers et al., 2010). LAB also have some other beneficial effects such as 
vitamin synthesis, improvement of mineral and nutrient absorption, degradation of 
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antinutritional factors, and/or modulation of GI physiology and reduction of pain per-
ception. Special probiotic strains may induce the expression of receptors on epithelial cells 
that locally control the transmission of nociceptive information to the GI nervous system 
(Rousseaux et al., 2007). Beneficial bacteria have enzymatic equipment which enables them 
to break down a wide variety of food constituents that cannot be metabolized by the host 
such as galactooligosaccharides, inulin, resistant starches, and antinutritional factors such as 
tannins or phytates responsible for the chelation of minerals including iron, zinc, mag-
nesium and calcium (Gilman & Cashman, 2006; Songre-Quattara et al., 2008; Cecconi et al., 
2009). They can also modify the host gut physiology by increasing the production of growth 
factors (Alberto et al., 2007). LAB may thus be of benefit to health and help protect against 
diseases, like CVD, diabetes, metabolic syndrome, etc. As far as OxS is at least one of the 
components of initiation and/or the development of the mentioned diseases thus any kind 
of agent which can prevent the development of harmful OxS has a principal impact. Pro-
biotics involve LAB or bifidobacteria of human origin. They can during the consumption 
period adhere to the epithelial cells of GI modulating the human physiological status via the 
gut associated immune system and/or directly due to the expression of receptors of GI 
and/or systematically. LAB beneficial effects are strain-specific. In vitro and cellular models, 
the probiotic properties of lactobacilli have been limited to few parameters such as the 
ability to survive low (pH 2-3) and bile salts, to produce pathogen inhibitory compounds 
(including hydrogen peroxide), to compete with energy availability or adhesion sites, and to 
enhance immune response (Ryan et., 2008; Todorov et al., 2008; Pfeiler & Klaenhammer, 
2009). Along with the probiotics themselves, there are metabiotics i.e, the metabolic by-
products of probiotics. Metabiotics are beneficial in promoting a healthy GI by creating an 
environment most favorable to probiotics, by nourishing the enterocytes, reinforcing 
mucosal barrier function, by maintaining or supporting epithelial integrity or signaling the 
immune system to limit inflammatory responses both in the gut and through influencing T-
cells throughout the body. The principal metabiotics are short-chain fatty acids but also 
other substances like polyamines (putrescine, spermidine, spermine) have an impact 
(Larqué et al., 2007). It has been demonstrated, that NO produced by LAB protects mucosa 
for damages and excessive permeability (Payne et al., 1993; Korhonen et al., 2001).  
Since 1993 when Kaizu and co-workers discovered antioxidative activity of LAB, a few of 
them have had effects in clinical human trials (Kaizu et al., 1993). One of them is 
antioxidative-antiatherogenic and antimicrobial probiotic Lactobacillus fermentum ME-3 
(LfME-3). Tartu University has patented this strain in Estonia, Russia, USA and Europe. 
LfME-3 (DSM 14241) is of human origin (Sepp et al., 1997) and has proven its safety as a 
probiotic exhibiting both antimicrobial and antioxidative benefits under different in vitro 
and in vivo conditions (Kullisaar et al., 2002, 2003; Truusalu et al., 2004; Songisepp et al., 
2005; Järvenpää et al., 2007). What makes this strain such a powerful multivalent 
antioxidant? It is confirmed that in vitro the superoxide anion scavenging efficiency of 
LfME-3 was more than 80-100 times stronger as compared with trolox or ascorbic acid 
(Ahotupa, personal communication). LfME-3 expresses Mn-superoxide dismutase (MnSOD) 
activity, can effectively eliminate hydroxyl and peroxyl radicals, and has the complete 
glutathione system (reduced glutathione, glutathione peroxidase, GPx, glutathione 
reductase, GRed) necessary for glutathione recycling, transporting and synthesis (Kullisaar 
et al., 2002, 2010). Mn-SOD is very important in the control of LP. Manganese and Mn-SOD 
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activity of LAB (not possessing catalase) is important for their survival in the oxidative 
milieu (milk, host) created by the production of hydrogen peroxide (Sanders et al., 1995). It 
has been shown that some LAB (L.gasseri) engineered to produce SOD reduce the 
inflammation in the case of colitis in interleukin-10-deficient mice (Carroll et al., 2007).  
Glutathione (L-gamma-Glu-L-Cys-Gly or GSH) is a major cellular non-enzymatic antioxi-
dant. It eliminates lipid- and hydroperoxides, hydroxyl radical and peroxynitrite mainly via 
cooperation with Se-dependent glutathione peroxidase (Zilmer et al., 2005). The GI surface 
is an important host organism-environment boundary and the interactions of gut microbes 
inside the intestinal lumen and mucosal cells are important for the host. An impaired 
environment such as the imbalance of GI microbiota, but also the increase of LP and 
decrease of the reduced GSH both at the GI surface and in the GI cells, are the mighty 
modulators causing different unhealthy outcomes in the host. In this process the involve-
ment of the glutathione system is crucial as GSH, besides its role as a crucial antioxidant, is 
the principal redox controller for a number of processes in cells. Glutathione-related data 
has impact for LfME-3 regarding at several aspects (cf. 5.2). Thus, confirmation of the 
presence of all glutathione system components in a specific concrete LAB gives very 
valuable information as it shows that a specific LAB strain has especially high oxygen and 
ROS tolerance under different stress conditions. An essential physiological trait for 
probiotics is tolerance to stress in the GI as well as during the production of functional foods 
(Ross et al., 2005). Beside that GSH has essential role in maintaining mucosal integrity. 
Studies have shown diminished GSH levels in inflammatory diseases of intestine and GSH 
supplementation has beneficial effect (Coskun et al., 2010). 
Evidently some probiotics are able to promote an elevation of the level of beneficial bacteria 
in the GI. In experiments and clinical trials, the administration of the LfME-3 strain has led 
to the improvement of the GI microbial ecology. More than a 10-fold increase of total 
lactobacilli counts in comparison with the individually different initial count was registered 
in the collected faecal samples (Mikelsaar & Zilmer, 2009). The metabolites secreted by 
LfME-3 into the GI tract could be used as a substrate by other lactobacilli. Adding LfM-3 as a 
probiotic into a dairy product (yoghurt, cheese, milk) also suppressed the putative 
contaminants of food (Salmonella spp., Shigella spp.,). The secreted substantial amount of 
hydrogen peroxide and the production of NO by LfME-3 are the main antimicrobial agents 
(Mikelsaar & Zilmer, 2009. Animal studies have confirmed that the increase in total LAB 
counts as much as the specific LfME-3 strain antioxidative action in the GI eradicated live 
salmonellas and prevented the formation of typhoid nodules in experimental Salmonella 
Typhimurium infections, resembling typhoid fever in humans (Truusalu et al., 2004, 2008). It 
was the first time that the antibiotic therapy of an invasive infection like enteric fever was 
shown to be more effective if administered together with a probiotic. 
5.2 Role of probiotics for systemic antioxidative defence (possible action 
mechanisms) 
Such information is limited. However, some specific multifunctional probiotics may have an 
influence on systemic (blood) antioxidative defence and the OxS status of host. Thus, to 
characterize the role of high-grade OxS in the pathogenesis of CVD, we will give an over-
view about the possible action mechanisms of probiotics on OxS-related indices of CVD. 
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On the basis of simplified general understandings it can be speculated that there are several 
factors that may have an impact on OxS. This is only one of the examples. It can be 
speculated that the suppression of Helicobacter pylori infection by some LAB (Wang et al., 
2004; Cruchet et al., 2003; Linsalata et al., 2004) may have a certain effect on the host OxS-
related indices in blood. However, such approaches are actually only speculations. Why? An 
analysis of scientific literature allows one to conclude that for a real effect on the systemic 
OxS-related indices of a host, a specific probiotic strain should have multifunctional 
bioquality: a) to have positive effects on GI total lactobacilli counts; b) to be able to suppress 
putative contaminants of food; c) to have biovaluable different antioxidative properties; d) 
to have a positive effect on OxS-related CVD markers, like TG, oxLDL, etc. In section 5.1. it 
was explained that the probiotic LfME-3 carries first three types (a,b,c) of properties. Thus, 
these multifunctional properties of LfME-3 may protect the host against both food-derived 
infections and help in the prevention of the oxidative damage of food. For example, the 
antioxidative protection provided by the LfME-3 strain for the prevention of the oxidative 
spoilage of semi-soft cheeses was found out (Järvenpaa et al., 2007). Thus, points a, b and c 
have an impact on the role of probiotics for systemic antioxidant defence. However, it is 
crucial also to have data (according to point d) about the specific influence of probiotics on 
OxS-related CVD markers. Since LfME-3 has been carefully investigated, concerning the 
latter we will use gathered information as a model to discuss possible mechanisms on how 
probiotics may have an influence on the OxS-driven CVD risk markers of a host.  
We repeatedly showed that administering a food products to humans comprising strain 
LfME-3 enhances the systemic antioxidative activity of sera (increases total antioxidative 
activity, TAA, or total antioxidative status, TAS), enhances the lag phase of LDL (increases 
oxi-resistance of LDL particles, i.e. suppresses production of atherogenic oxLDL) and dec-
reases level of oxidized glutathione (pro-oxidant), oxLDL and BCD-LDL of sera (Kullisaar et 
al., 2003, 2011; Mikelsaar et al., 2007). Clinical trials showed that the strain LfME-3 alleviates 
inflammation and OxS-associated shifts in gut, skin and blood (Kullisaar et al., 2003, 2008; 
Kaur et al.2008). This realizes via complicated cross-talk between probiotic and host body 
cells via the integrated influence of several factors of strain LfME-3 like having complete 
glutathione system, the expression of antioxidative enzymes, the production of CLA and 
NO by strain LfME-3, etc (Mikelsaar & Zilmer, 2009; Kullisaar et al., 2010, 2011). This strain 
survives in different fermentation processes of milk due to its good tolerance to low 
temperature, acid and salt (Songisepp et al., 2004; Songisepp, 2005) and is able for temporal 
colonization of the GI tract of the consumer. All this is very important as the GI surface is a 
crucial host organism-environment boundary and the interactions of GI microbes inside the 
intestinal lumen and mucosal cells have impact for the metabolic activity both microbes and 
host cells. An impaired environment (the imbalance of GI microbiota, the increase of LP, 
decrease of the GSH) both at the intestinal surface and in the intestinal cells, are substantial 
modulators causing unhealthy outcomes in the host. In addition, data that these cellular 
modulators of the intestinal mucosal status can be repaired by applying of strain LfME-3 
was confirmed by using a mouse model of experimental S. Typhimurium infection (Truusalu 
et al., 2004, 2008). Concerning this process the involvement of the glutathione system is 
crucial as GSH, in addition its role as a crucial cellular antioxidant, is the principal redox 
controller for a number of cellular processes. Glutathione-related information has impact for 
LfM-3 regarding next information: a) a recent adapted conceptions of OxS is advanced as “a 
disruption of redox signalling and control” (Jones, 2006) or “steady-state ROS” (Lushchak, 
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2011) that emphasize an impact of GSH and its redox ratio for the quantification of OxS and 
the signalling role of GSH, described previously (Karelson et al., 2002; Zilmer et al., 2005); 
and b) there exists the possibility for the effective participation of LfM-3 in both enzymatic 
and non-enzymatic glutathione-driven protection as this strain carries all components 
needed for functionality of complete glutathione system (Kullisaar et al, 2010). It is 
interesting to add that recently it has been shown that just L. fermentum as a species 
significantly counteracted the depletion of colonic GSH content induced by some 
inflammatory processes (Peran et al., 2007) that also supported our understandings. There 
exists also a correlation between the glutathione redox ratio and DNA oxidative damages 
(de la Asuncion et al., 1996). Thus, consumption of multivalent probiotic LfME-3, which 
produces glutathione and has complete glutathione redox cycle enzymes (GPx and GRed), 
may contribute to the reduction of lipid hydroperoxides in the GI tract and in hepatocytes 
and prevent them from entering the circulation (Kullisaar et al., 2010). This may lead to an 
improvement of systemic picture in the host organism. 
Data showed that the improvement of the intestinal extra- and intracellular environment 
yielded beneficial changes of some general (systemic) biochemical indices of the host 
organism. The administration of LfME-3 to healthy volunteers and atopic adults results in a 
reduction of LP and a counterbalance of the glutathione system both in blood and in skin. In 
addition, in several trials LfME-3 has beneficial effect on the blood LDL fraction: the 
prolongation of its resistance to oxidation, the lowering of the content of oxLDL (a potent 
inflammatory and atherogenic factor) and BDC-LDL and the enhancement of the TAS of 
sera (Kullisaar et al., 2003, 2011; Songisepp et al., 2005; Mikelsaar et al., 2008). In trial on 
elderly persons the lower content of oxLDL was significantly predicted by the higher count 
of live lactobacilli in the GI tract. Evidently, both the number special antioxidative 
characteristics of strain LfME-3 and the increase in lactobacilli counts induced by admi-
nistration of LfME-3 are responsible for such effect on host lipoprotein circulation/me-
tabolism. As we mentioned before, the status of OxS and blood lipoproteins are both related 
to the pathogenesis of different diseases, including inflammation-related diseases and CVD. 
Dzau et al (2006) presented in Circulation the pathophysiological continuum showing that 
traditional CVD risk factors all promote OxS and endothelial dysfunction as the first steps in 
a cascade of pathological events. Elevated OxS leads to the overproduction of oxLDL and 
the latter has accepted as one of the new systemic markers of the development of CVD 
(Bonaterra et al., 2010). The higher levels of circulating oxLDL are strongly (much more than 
LDL-cholesterol) associated with an increased incidence of metabolic syndrome already in 
people who are currently young and healthy according to a large population-based study 
(Holvoet et al., 2008). Next, oxLDL is an important determinant of structural changes of the 
arteries already in asymptomatic persons (Kals et al., 2006; Kampus et al., 2007). An 
increased production of atherogenic and inflammatory oxLDL within the vessel wall 
suppresses immunity-related cells, including regulatory T cells (George, 2008) exerting 
antiatherogenic and antiallergic effects.  
The influence of strain LfM-3 on host systemic OxS markers has been showed also via the 
decline of the values of isoprostanes and 8-OHdG in urine (Kullisaar et al., 2003, 2008; 
Songisepp et al., 2005). These indices are very informative for systemic OxS burden 
(Halliwell & Gutteridge, 1999). Evidently the systemic antioxidative effect of strain LfME-3 
begins from the alleviation of the OxS- and inflammation-related abnormalities in the GI 
cells that lead to the assembling of particles of chylomicrons, LDL and HDL with a higher 
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bioquality (with lower levels of harmful oxidation products) and higher concentrations of 
antioxidant factors/enzymes. The higher bioquality of assembled lipoprotein particles leads to 
improvement of their metabolism/circulation in the host body. This is one of the explanations 
why strain LfME-3 exerted the prolonged resistance of the blood lipoprotein fraction to oxi-
dation, lowered the level of oxLDL and enhanced the TAC of sera in both healthy and 
problematic consumers (Kullisaar et al., 2003, 2006, 2008, 2011; Songisepp et al., 2005). Recently 
it was showed that administration of strain LfME-3 alleviated the postprandial elevation of TG 
levels in the blood, and improves HDL bioquality (elevates of paraoxonase level in HDL 
particles) (Kullisaar et al., 2006; 2008; 2011). The antioxidant activity of HDL can be expressed 
via several mechanisms (Bruckert & Hansel B, 2009). Paraoxonase (PON), an antioxidant 
enzyme associated with HDL, hydrolyzes oxidized phospholipids and inhibits the LDL 
oxidation that is an important step in atherogenesis. In animals, the addition of oxidized lipids 
to the circulation reduces PON activity, and diets rich in oxidized fat accelerate the 
development of aterogenesis (Sutherland et al., 1999). Removal and inactivation of lipid 
peroxides accumulating during LDL oxidation may be the central mechanism accounting for 
HDL antioxidative properties and when HDL particles have poor bioquality (low antioxidant 
properties and anti-atherosclerotic potency), they may have even inflammatory effect (Navab 
et al., 2006). The increase in PON activity after LfME-3 consumption shows that protection of 
LDL particles against oxidative modification by ROS is improved. PON inhibits atherogenesis 
by hydrolyzing lipid hydroperoxides and cholesterol ester hydroperoxides, reducing 
peroxides to the hydroxides, and hydrolyzing homocycteine thiolactone which prevents 
protein homocycteinylation (Beltowski et al., 2003; Durrington et al., 2005). Therefore, an 
elevation of PON activity should decrease the level of oxLDL. Antioxidant action of HDL is 
noted as one of the principal mechanisms mediating its cardioprotective effect (Hansel et al., 
2006). It should be noted that HDL-associated antioxidant activity information is also 
supported both by data of anti-inflammatory effects of strain LfM-3 on the liver (Truusalu, et 
al., 2008) and by a hepato-protective role for PON against inflammation and liver disease 
mediated by OxS (Marsillach et al., 2009). Next, it is accepted that postprandial abnormal 
events are crucial concerning the development of CVD (Lopez-Miranda et al., 2006). Recently a 
postprandial decrease of three different OxS-related parameters (oxLDL, BCD-LDL, Beta2-
GPI-OxLDL) was established (Kullisaar et al., 2011). Thus, the foodstuffs enriched with LfME-3 
substantially improves postprandial indices both of lipid/lipoproteins and OxS (Kullisaar et 
al., 2006; 2008; 2011). The beneficial influence of such enriched food on the postprandial lipid 
metabolism and OxS is important as many links between OxS and metabolic syndrome occur 
during the postprandial period. These include an excessive and prolonged elevation of blood 
TG levels, impairment of the endothelial function, an intestinal overproduction of 
chylomicrons, a redundant load for insulin production, the elevation of levels of atherogenic 
oxLDL and possible disturbances in the antioxidative activity of HDL (Bae et al., 2001; Jackson 
et al., 2007; Perez-Martinez et al., 2009; Hopps et al.,2010). To summarize, a positive 
modulation of the postprandial situation, including postprandial OxS, is an important target 
for dietary preventive actions concerning cardiovascular diseases.  
6. Possibilities of the oxidative stress-targeted administration of probiotics 
6.1 Functional food and capsules 
Functional foods are foods or dietary components (incl. probiotics) that may provide a 
health benefit beyond basic nutrition. Probiotic products may be conventional foods 
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consumed for nutritional purposes, but also for the probiotic effect or ”medical foods” - the 
primary purpose is that food formulation is a delivery vehicle for probiotics or metabiotics 
(beneficial by-products of probiotics). Probiotics are also available as dietary supplements in 
capsule, powder or liquid extract form. In functional food products no more than two 
probiotic strains are used in combination as a rule. Probiotic dietary supplements can consist 
of one single strain or mixed cultures of two or even more strains. There is some evidence 
that multi-strain probiotic mixtures could be more effective than single strains, including 
strains that are components of the mixtures themselves (Chapman et al., 2011). 
Many functional foods can be found in a form of synbiotics. Synbiotics have been defined as 
mixtures of probiotics and prebiotics (dietary fiber) (Schrezenmeir & de Vrese, 2001; Saulner 
et al., 2007). One of the main benefits of synbiotics is the increased persistence of probiotics 
in the GI tract. Probiotic dietary supplements (capsules, powders and chewing tablets) often 
additionally contain amino acids, vitamins and/or prebiotics. Probiotic functional foods 
could be fermented or non-fermented foods. Traditionally dairy products are the carriers of 
probiotics. A large variety of probiotic dairy products with particular functional properties 
are available on the market worldwide. Fermented dairy products, especially yoghurts and 
yoghurt-like products are most widely used. There is a technological reason for using dairy 
products as probiotic carriers: dairy products have been optimized for the survival of starter 
cultures (mostly LAB) and are relatively easily adapted to grant the survival of probiotic 
strains as well. Besides, dairy products have other advantages over other formulations. 
Dairy foods are refrigerated. Probiotic bacteria in cultured dairy products benefit, as they 
remain the most stable in a refrigerated storage condition. 
Cheese is used as a probiotic vehicle to a lesser extent than fermented milk products (Son-
gisepp et al., 2004; Ross et al., 2005, Ibrahim et al., 2010). Cheese (especially cheddar) may 
offer certain advantages over other probiotic products such as yogurt or milk. The cheese is 
a protective environment for the microbes, as the anaerobic conditions, relatively high fat 
content and buffering capacity of the cheese matrix helps to protect the probiotic strain in 
the product. The longer cheese is aged for, the higher density of probiotic microbes and 
metabiotics it will contain. Although the sensitivity of probiotics to physical and chemical 
stress, heat and acidity makes the product development challenging for other type of food 
products, probiotics in addition to dairy have been applied in nontraditional foods such as 
chocolate, energy bars, juices, smoothies, vegetables, breakfast cereals and even meat 
products like salami etc (Saarela et al., 2000, Siro et al., 2008). 
The physiological state of the bacteria in a functional product is an important factor for the 
survival of the probiotic strain in the product, but most important is the manifestation of 
functional/health promoting properties in the human body after ingestion. There is a crucial 
difference between functional food and dietary supplements concerning the physiological 
state of the probiotic culture. Microbes are often freeze dried by the process of lyophilization 
before being manufactured as a dietary supplement (free-flowing powders, capsules, 
tablets). The dryness keeps the probiotic in a quiescent state during storage, while in food 
products the bacteria are in a vegetative state with a potentially active metabolism. Besides, 
dried probiotic cultures may have undergone several stressful processes during their 
production that damage the cells and may affect their viability (Champagne et al., 2011). 
Milk as a delivery vehicle has a dual effect on the probiotic additive: the buffering capacity 
of milk protects the viability of the strain against the stomach’s acidic conditions. In addition 
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to the protective effect, which affects the survival of the ingested probiotic, milk contains 
lactose, minerals, vitamins and bioactive peptides, which enhance the metabolic activity of 
the ingested probiotic strain in the GI tract.  
6.2 Special clinical trial with lactobacillus strains concerning oxidative stress 
Probiotics have been advocated for the prevention and treatment of a wide range of 
diseases, and there is a growing evidence for their efficacy in some clinical scenarios. 
Probiotics are now widely used in many countries by consumers and in clinical practice. 
Given the increasingly widespread use of probiotics, a thorough understanding of their 
benefits is imperative. The properties of different probiotic species vary and can be strain-
specific. Therefore, the effects of one probiotic strain should not be generalized to others 
without confirmation in separate studies. The proposed health benefits of probiotics have 
undergone increasingly rigorous scientific evaluation in recent years, and there is now 
strong evidence for their use in treating and preventing some human diseases. 
A meta-analysis of randomized controlled trials (RCTs) has shown that many probiotics are 
effective in preventing antibiotic-associated diarrhoea (McFarland, 2006; Ruszczynski et al., 
2008). A separate meta-analysis of RCTs has shown a variety of probiotics to be effective in 
the treatment of infective diarrhea in both adults and children (Allen et al., 2011) acute 
waterly diarrhoea (Dutta et al., 2011), C. difficile diarrhoea (Plummer et al., 2004), ulcerative 
colitis and necrotizing enterocolitis (Sari et al., 2011). There is also support from RCTs for the 
efficacy of a probiotic mix in patients with inflammatory bowel disease (Kajander et al., 
2007; Hovyeda et al., 2009). Nevertheless the evidence to date suggests that the major 
clinical effects of probiotics are seen in prevention GI disorders, probiotic therapy has also 
been explored in non-GI diseases, including the treatment of atopic eczema in children and 
adults (Kalliomaki et al., 2001, 2007; Kaur et al., 2008). A specialprobiotic, LfME-3, offers a 
good potential also in cardiovascular health management. LfME-3 an antioxidative-
antiatherogenic and antimicrobial probiotic decreases OxS level in human body. The 
foodstuffs enriched with this probiotic decrease the level of oxidized LDL, increases the 
level of HDL, modulates postprandial lipid profile and OxS, and decreases the level of 8-
isoprostanes in urine (the markers of systemic OxS) and body overall OxS-load, indicating 
an atherogenic potential (Kullisaar et al., 2002, 2003, 2011; Songisepp et al., 2005; Mikelsaar, 
Zilmer, 2009, Table 2). 
Intense physical activity increases oxygen consumption and inflammation induced by tissue 
damage and the probiotic consumption decreased the OxS level (Martarelli et al., 2011). The 
emerging evidence of a role for GI microbiota on central nervous system functions suggests 
that the oral intake of probiotics may have beneficial consequences on mood and 
psychological distress by the competitive exclusion of deleterious GI pathogens, decreases 
in proinflammatory cytokines and communication with the CNS, leading to changes in 
neurotransmitter level or function (Logan; Katzman, 2005; Messaoudi et al., 2011). Probiotics 
are widely used to promote host health. Despite the huge amount of in vitro and in vivo 
studies (including cell culture, animal and human studies) we still lack data on the exact 
mechanisms involved. Our recent results by using MALDI-TOF spectrometry proteomic 
analysis confirmed that the concentration of glutathione in the blood of the probiotic LfME-3 
users increases substantially; that is in good correlation with earlier results. Thus, new 
proteomic and metabolomic data about LAB and the relation between the colonic microbiota 
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and host status could give new information regarding the mechanism of probiotic beneficial 
effects, including the effects on the OxS status of a host organism. 
It has been demonstrated that functional food products with special Lactobacillus sp. strains 
have the potential to lower blood pressure (Naruszewicz et al., 2002). We demonstrated that 
semi-hard Edam-type cheese comprising the strain L. plantarum TENSIA (DSM 21380, 
property of Bio-Competence Centre of Healthy Dairy Products LLC) helps to maintain 
normal systolic and diastolic blood pressure in healthy adults and elderly subjects, thus 
supporting the functions of the cardiovascular system (Songisepp et al. 2009). Lately we 
have found that a 3-week consumption of 50g of probiotic cheese comprising L. plantarum 
TENSIA (daily dose 1010 of probiotic viable cells per serving) decreased both diastolic 
(diapason of change: -3.67.1 (median -2.3; p=0.01) and systolic (diapason of change: -4.48.2 
(median -4.0, p=0.01) blood pressure in adult subjects with high normal blood pressure (130-



































Table 2. Effects of foodstuffs enriched with probiotic LfME-3 on both oxidative stress-related 
indices and HDL-cholesterol level of human body. oxLDL, oxidized low-density lipoprotein; 
BDC-LDL, baseline conjugated diene in LDL; GSSG, oxidized glutathione; GSH, reduced 
glutathione; HDL-Chol, high-density lipoprotein cholesterol  
In the elderly, the consumption of the same amount of probiotic cheese in a somewhat lower 
daily dose of probiotic viable cells per serving (108) decreased both diastolic (diapason of 
change -4.0 ± 5.2mmHg, median -5mm Hg; p= 0.004) and systolic (diapason of change: -
5.9±13.4, median -12 mmHg; p=0.038). 
It is repeatedly declared that new approaches in global CVD risk reduction are needed 
(Elliott, 2008). It is stated that for the prevention of CVD risk the anti-inflammatory agents 
and antioxidants are considered as a possible “third great wave”’ (Bhatt, 2008). Evidently, 
the prevention complexes of several diseases could become more successful by including 
probiotics with a special multivalent (including antioxidative properties) biopotency. 
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